Sky Century Investment (SKYI) Cash & Equivalents (2012 - 2026)

Sky Century Investment (SKYI) reported Cash & Equivalents of $3360.0 for Q1 2026, up 619.49% quarter-over-quarter from $467.0 in Q4 2025.

Sky Century Investment (SKYI) Cash & Equivalents (2012 - 2026) Analysis & Trends

Sky Century Investment (SKYI) has 5 years of Cash & Equivalents data on file, last reported at $3360.0 in Q1 2026.

Cash & Equivalents for Q1 2026 came in at $3360.0, changed N/A year-over-year; the trailing twelve-month figure through Feb 2026 was $3360.0 (changed N/A YoY), and the FY2025 annual result was $477.0, changed N/A from the prior year.
Cash & Equivalents grew to $3360.0 in Q1 2026 per SKYI's latest filing, from $467.0 in the prior quarter.
Over five years, Cash & Equivalents peaked at $11312.0 in Q2 2025 and troughed at $467.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	3.74 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	1.94 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	1.28 Bn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	40.42 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	266.50 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	428.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	351.55 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	222.27 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	498.58 Mn
10	Sky Century Investment	-	-	31,666.00	3,360.00

Download Data